BIO-FD&C CO.,LTD.: debt-to-equity, ROE and more
KOSDAQ, Legal name BIO-FD&C CO.,LTD.
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 5.2%
- Equity ratio
- 95.0%
- ROE
- 9.6%
- Op. margin
- 32.6%
- Rev. growth
- 19.4%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 45.1% | 68.9% | 18.3% | 26.2% | n/a |
| FY2022 separate | 11.4% | 89.7% | 8.2% | 30.8% | 32.4% |
| FY2023 separate | 7.2% | 93.3% | 9.5% | 32.3% | -1.7% |
| FY2024 separate | 6.6% | 93.8% | 7.1% | 30.2% | 3.0% |
| FY2025 separate | 5.2% | 95.0% | 9.6% | 32.6% | 19.4% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩12.0B | ₩15.9B | ₩15.6B | ₩16.1B | ₩19.2B |
| Operating profit | ₩3.1B | ₩4.9B | ₩5.0B | ₩4.9B | ₩6.3B |
| Pre-tax income | ₩3.3B | ₩5.4B | ₩7.2B | ₩5.2B | ₩7.9B |
| Net income | ₩2.9B | ₩4.3B | ₩5.6B | ₩4.5B | ₩6.7B |
| Total assets | ₩23.0B | ₩59.0B | ₩62.8B | ₩67.3B | ₩73.4B |
| Total liabilities | ₩7.2B | ₩6.1B | ₩4.2B | ₩4.2B | ₩3.7B |
| Total equity | ₩15.9B | ₩53.0B | ₩58.6B | ₩63.1B | ₩69.8B |
| Paid-in capital | ₩3.7B | ₩4.3B | ₩4.3B | ₩4.3B | ₩4.3B |
| Debt/equity (source value) | 45.1% | 11.4% | 7.2% | 6.6% | 5.2% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2005-11-11
- Listed
- 22/02/21
- Employees
- 78
- Auditor
- 동성회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1201110388092
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 바이오에프디엔씨Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.